December 21, 2020 10:14 AM ESTUpdated 10:29 AM

News briefing: GlaxoSmithKline adds to flurry of dealmaking; Takeda strikes $322M deal to offload a non-core portfolio

Conner Mitchell

Nicole DeFeudis

Editor

As 2020 winds down, British drugmaker GlaxoSmithKline continues a flurry of biotech dealmaking — this time focused on small molecule therapeutics that target transmembrane …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

News briefing: GlaxoSmithKline adds to flurry of dealmaking; Takeda strikes $322M deal to offload a non-core portfolio

Conner Mitchell

Nicole DeFeudis

Editor

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

News brief­ing: Glax­o­SmithK­line adds to flur­ry of deal­mak­ing; Take­da strikes $322M deal to of­fload a non-core port­fo­lio

Editor

Sign up to read this article for free.

News briefing: GlaxoSmithKline adds to flurry of dealmaking; Takeda strikes $322M deal to offload a non-core portfolio